Genomic instability is a universal hallmark of all cancers. Many of the most commonly used chemotherapeutic agents target this genomic instability by directly damaging the DNA, which results in tumour cell death.
05-12-2020 Joshua Burgess, Ph.D.
The CRISPR/Cas9 system has made targeted gene editing easily accessible for research and therapeutic purposes.
05-07-2020 James Chon, Ph.D.
Genome editing has always been a challenging area as a means to provide more efficient ways to create a meaningful change in the genome.
05-06-2020 Dr. Edward Wong, Field Application Scientist, GenScript
Tips for Successful ELISA kit Development
04-29-2020 Dr. Pei Liu, Senior Scientist, GenScript
Neoantigen based personalized immuno-oncology drugs are a relatively new therpauetic avenue that have shown strong anti-tumor efficacy in the clinic.
04-29-2020 Raymond Miller, Ph.D.
Adeno-Associated Viruses (AAVs) have been a prevalent platform for gene delivery due to their simple structure and genome, lack of pathogenicity, and low immunogenicity.
04-22-2020 Susan Butler, Suh Lab, Department of Bioengineering, Rice Universit